Navigation Links
Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million
Date:11/21/2008

SEATTLE, Nov. 21 /PRNewswire/ -- Attorneys representing consumers and third-party payers today announced a proposed landmark $350 million settlement with healthcare services giant McKesson (NYSE: MCK) to settle allegations the company fraudulently inflated the price of more than 400 prescription drugs by manipulating drug-pricing benchmarks.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO)

The lawsuit, filed under the Racketeer Influenced and Corrupt Organizations Act (RICO), claimed McKesson conspired with drug publishing company First DataBank (FDB) to fraudulently inflate the widely used Average Wholesale Price (AWP) figures, which insurance companies, retailers and others use to calculate the purchase price, payments and co-payments of the most common prescription medications.

The settlement is one of the nation's largest RICO settlements, and if approved by the court will be distributed among third-party payers, cash and co-pay consumers.

"The impact of this settlement is very significant for all who have paid for brand name drugs," said Steve Berman, managing partner at Hagens Berman Sobol Shapiro and lead counsel.

Retailers typically purchase drugs based on the wholesale acquisition cost (WAC) and base co-pays and charges to third-party payers using the AWP, court documents show. The suit alleged McKesson and FDB increased the AWP spread between WAC and AWP from 20 to 25 percent beginning in 2001, allowing retail clients to reap larger profits at the expense of consumers and third-party payers, such as insurance companies. By 2004, nearly every common prescription drug enjoyed a 25 percent spread between the two benchmarks.

Plaintiffs claimed McKesson orchestrated the scheme to put the company in good favor with retailers who might otherwise choose to purchase wholesale prescriptions from McKesson's competitors in the highly competitive wholesale arena. Retailers make a profit off the increased spread created by the McKesson engineered scheme.

Court documents state that FDB claimed it surveyed a number of wholesalers when it published its AWP benchmark, when in fact it relied on McKesson as its sole source of information. Beginning in 2001 and through 2003, McKesson changed the mark up on hundreds of brand name drugs from 20 percent to 25 percent as part of the scheme.

"For years consumers have been burdened with inflated drug prices and as a firm we feel a sense of gratitude in being able to ease that burden for many," said Berman. "Today's settlement goes a step further in helping to correct corrupt business practices and rectify a damaging situation to consumers."

Plaintiffs in the case include those who paid for the brand name drugs and whose payments were tied to AWP. This includes all purchases from Aug. 1, 2001 until March 15, 2005. The plaintiffs propose the $350 million disperse among three groups: insurers and other entities that paid for drugs ($288,675,000), consumers who paid a graduated co-payment ($20,900,000), and cash paying consumers ($40,425,000).

A settlement approval hearing has not yet been set.

For more information on this case and to sign up as a consumer or third-party payer you can visit the Hagens Berman Web site at http://www.hbsslaw.com/McKesson_classaction.htm.

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix, San Francisco and New York. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation, one of the largest anti-trust settlements in history; a $340 million recovery on behalf of Enron employees; over $200 million in proposed settlements in the Average Wholesale Price Litigation; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

     CONTACT:

     Steve Berman (206) 623-7292              Mark Firmani (206) 443-9357
     Hagens Berman Sobol Shapiro              Firmani + Associates Inc.
     Steve@hbsslaw.com                        Mark@firmani.com

'/>"/>
SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign
2. Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics
3. Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation
4. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
5. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
6. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
7. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
8. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
9. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
10. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
11. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: